DNAnexus, Inc. Overview
Pro stress-test →DNAnexus is a provider of cloud-based genome informatics and data management platform that enables enterprises and organizations in genomic medicine to analyze raw sequencing data, integrate genomic data with clinical and phenotypic information, and collaborate seamlessly. The company addresses a critical bottleneck in precision medicine: geneticists predict more than 500 million genomes will be sequenced by 2025 generating 40 exabytes of data, but only a fraction is currently utilized for drug discovery.
Strategic Profile
Pro stress-test →DNAnexus has raised $473M in funding from investors like Google Ventures, TPG and First Round Capital, with its most recent major financing being a Series H round for $200M in March 2022 led by Blackstone. The company ranks 2nd among 355 active competitors and 2nd in terms of total funding among its peers, positioning it as a well-capitalized leader in biomedical data infrastructure for the life sciences industry.
Competitive Landscape
Pro stress-test →DNAnexus's top competitors include Evotec, Insitro, and Fabric Genomics. Additional competitors include Partek, Benchling, InterpretOmics, PointCross Life Sciences, and Golden Helix. These competitors span different segments of the genomic data workflow—some focus on software platforms, others on specialized analytics—but DNAnexus's breadth across data management, analytics, and collaboration gives it competitive leverage in enterprise life sciences accounts.
Industry Context
DNAnexus, Inc. operates in Genomic data management and bioinformatics platforms.
Key facts
Founded: 2009 · Headquarters: Mountain View, US · Employees: 277 · Revenue: Estimated $50M–$100M · Market cap: N/A